Market entry of generic drugs is delayed and there is a decline in the number of novel medicines reaching the market, according to the European Commission's final report on competition in the pharmaceutical sector.
Vastavalt farmaatsiasektori konkurentsi käsitleva sektoriuuringu lõpparuandele, mille on koostanud Euroopa Komisjon, jõuavad geneerilised ravimid turule hilinemisega ning turule jõuab ka vähem uusi originaalravimeid.